Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)

Federal funding opportunity PAR-25-211 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes June 2, 2027

Posted: October 31, 2024
Closes: June 2, 2027
Cost sharing: No
Instrument: Grant
Assistance listing: 93.393, 93.121, 93.213, 93.313, 93.866
Category: Education, Health
Archives: July 8, 2027

Program funding history

Awards made under Assistance Listing 93.393 across FY2024–FY2026, from public federal spending records.

FY2024 obligated: $730.8M
FY2025 obligated: $803.1M
FY2026 (to date) obligated: $305.7M
Awards in window: 2,902

Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Dana-farber Cancer Institute, Inc., Sloan-kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill

Source: USAspending.gov · refreshed July 2026

Synopsis

The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).

Who can apply

Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Private institutions of higher education
Special district governments
Small businesses
State governments
City or township governments
County governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
PAR-25-144 · National Institutes of Health · closes January 7, 2028
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
PAR-25-143 · National Institutes of Health · closes January 7, 2028
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
PAR-25-233 · National Institutes of Health · closes January 7, 2028
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
PAR-25-221 · National Institutes of Health · closes January 7, 2027
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
RFA-CA-24-026 · National Institutes of Health · closes September 28, 2026
Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
PAR-25-101 · National Institutes of Health · closes August 11, 2027

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts